Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus

Ann Transl Med. 2018 Apr;6(7):130. doi: 10.21037/atm.2018.02.20.

¹ Department of Medicine, Division of Cardiology, Mount Sinai Hospital, New York, NY, USA.
² School of Medicine, University of Crete, Heraklion, Greece.
³ Iatriki Diagnosi Group, PC, Athens, Greece.
⁴ Department of Medicine, Bronx-Lebanon Hospital Center, Bronx, NY, USA.
⁵ Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA.
⁶ Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA.

No abstract available

Publication types